-
Mashup Score: 0LISTEN TO THE EXPERTS - 8 hour(s) ago
Sponsored by Novartis US Medical Affairs Elevated lipoprotein(a) (Lp[a]) represents the most common type of genetic dyslipidemia. 1 Elevated Lp(a) levels occurring in 20% of the general population, particularly in certain races and ethnicities. 2 More than 70 million people in North America and 1.5 billion people globally are affected. 2,3 Lp(a) is the only apo(a)-containing lipoprotein. 4 Elevated Lp(a) is an independent, genetic, and causal risk driver of atherosclerotic cardiovascular disease (ASCVD).
Source: www.ajmc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
At the 30th European Hematology Association (#EHA2025) Congress, #hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide. Watch our recap! https://t.co/Smsdjq4kMQ
-
-
Mashup Score: 0
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Learn how enrolling in traditional Medicare plus supplemental coverage or Medicare Advantage reduces access and affordability issues for older adults, in a recent #AHRQ-funded study published in @AJMC_Journal. https://t.co/EbU18WLtrt https://t.co/fwH5XpmnAi
-
-
Mashup Score: 0FDA Approves Garadacimab-gxii in Hereditary Angioedema - 13 hour(s) ago
Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
The FDA granted approval to CSL’s garadacimab-gxii (Andembry), a first-in-class factor XII (FXIIa) inhibitor for patients with hereditary angioedema (HAE). Read more! https://t.co/MxfTpFOQa4 https://t.co/fuRUWpwId5
-
-
Mashup Score: 0
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Learn how enrolling in traditional Medicare plus supplemental coverage or Medicare Advantage reduces access and affordability issues for older adults, in a recent #AHRQ-funded study published in @AJMC_Journal. https://t.co/EbU18WLtrt https://t.co/fwH5XpmnAi
-
-
Mashup Score: 2Unaddressed Adverse Effects Undermine Patient Confidence in Lymphoma, CLL Care Plans: Lorna Warwick - 1 day(s) ago
Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia (CLL), according to Lorna Warwick, CEO of Lymphoma Coalition.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
In this interview, @LornaWarick, CEO of the Lymphoma Coalition / @knowyournodes, discusses the adverse effects experienced by patients with #lymphoma and #chroniclymphocyticleukemia, and how it impacts their well-being if left unaddressed. Watch now! https://t.co/YhzTyMzgDt
-
-
Mashup Score: 0
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Learn how enrolling in traditional Medicare plus supplemental coverage or Medicare Advantage reduces access and affordability issues for older adults, in a recent #AHRQ-funded study published in @AJMC_Journal. https://t.co/EbU18WLtrt https://t.co/fwH5XpmnAi
-
-
Mashup Score: 0Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD - 2 day(s) ago
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of Hope will host a virtual breast cancer forum to review key studies presented at ASCO.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
#Trastuzumabderuxtecan (T-Dxd) is highly effective in HER2+ #breastcancer—but interstitial lung disease #ILD risk remains a serious concern, new research presented at #ASCO2025 finds. Read more: https://t.co/vSpis1Q2H8
-
-
Mashup Score: 0
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
How are bispecific and trispecific antibodies transforming myeloma care? Our new AJMC video from ASCO 2025 breaks it down. Plus, insights from MDA 2025 and how tech could ease rural staffing gaps. In the meantime, stay up to date: https://t.co/bb8vCnu8uF #oncology #healthcare https://t.co/kjKaq851Ms
-
-
Mashup Score: 0Clinical Perspectives Presented by: - 2 day(s) ago
Five-Year Outcomes With First-Line Nivolumab + Ipilimumab With Chemotherapy vs Chemotherapy in Patients With Metastatic NSCLC in CheckMate 9LA Please see US Full Prescribing Information for OPDIVO. Please see US Full Prescribing Information for OPDIVO. Thoracic Oncologist, Clinical Professor in Oncology at Stanford University, CA Chief, Department of Oncology in Palo Medical Oncologist, Cancer Care University of Central Florida, FL Thoracic Oncologist, Clinical Professor in Oncology at Stanford University,
Source: www.ajmc.comCategories: General Medicine NewsTweet-
What are the clinical implications of 5-year CheckMate 9LA results in metastatic #NSCLC? Experts discuss long-term impact of nivolumab + ipilimumab + chemo vs chemo alone, key insights, and evolving treatment strategies. Get the #ClinicalPerspectives: https://t.co/2xdXwNiNf5
-
SPONSORED: Deepen your understanding of elevated Lp(a) levels with AJMC's new Interactive Tool. Access expert insights and comprehensive academic resources all in one place. Explore now: https://t.co/WTvwQTivlS https://t.co/uCozIW2wKM